Abstract Number: 0641 • ACR Convergence 2024
Predictive Validity of Coronary Artery Calcium Scoring in Low Risk Systemic Lupus Erythematous Patients
Background/Purpose: Traditionally, a coronary artery calcium (CAC) score of zero is associated with low rates (0.1-0.2% annualized risk) of major adverse cardiovascular outcomes (MACE). While…Abstract Number: 0645 • ACR Convergence 2024
Mortality and Ethnicity in Adults with Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Analysis
Background/Purpose: Ethnicity and health outcomes are intrinsically interrelated, although mechanisms are complex. Systemic lupus erythematosus (SLE) is a disease with higher incidence in non-White populations…Abstract Number: 0634 • ACR Convergence 2024
Clinical Relevance of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) in Predicting Lupus Outcomes: A 5-Year Longitudinal Cohort Study
Background/Purpose: Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) is a newly developed tool for assessing disease activity in SLE patients. Despite external validation in diverse…Abstract Number: 0567 • ACR Convergence 2024
Alteration of JAK-STAT Signaling in an Axial Spondyloarthritispatient with TYK2 Variants
Background/Purpose: Tyrosine kinase 2 (TYK2) is a member of the Janus kinase family that associates with the cytoplasmic domain of type I/II cytokine receptors and…Abstract Number: 0629 • ACR Convergence 2024
Evaluating the Concordance Between SRI4 and BICLA Using Placebo Data from Randomized Controlled Trials of Patients with Active Systemic Lupus Erythematosus
Background/Purpose: British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) and Systemic Lupus Erythematosus Responder Index 4 (SRI4) responses are the most common primary…Abstract Number: 0610 • ACR Convergence 2024
Clinical Evaluation on IFI44L Gene Methylation Detection for Diagnosis of Systemic Lupus Erythematosus by Methylation Sensitive High Resolution Melting (MS-HRM)
Background/Purpose: To evaluate the clinical effectiveness of IFI44L gene methylation detection for the diagnosis of Systemic Lupus Erythematosus (SLE) by MS-HRM, to determine the relative…Abstract Number: 0639 • ACR Convergence 2024
Delayed Diagnosis in Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-systemic autoimmune disease of unknown etiology. Diagnosis is often delayed because it frequently mimics symptoms of other diseases;…Abstract Number: 0425 • ACR Convergence 2024
Use of bDMARDs During Pregnancy After Preconceptional Counseling in Spanish Patients with Rheumatic Diseases
Background/Purpose: Current recommendations advocate maintaining pregnancy-compatible bDMARDs during pregnancy (mainly TNF inhibitors) and monitoring disease activity before conception to improve disease and pregnancy outcomes. Recently,…Abstract Number: 0644 • ACR Convergence 2024
Scoping Literature Review to Identify Candidate Domains for the SLE OMERACT Core Outcome Set
Background/Purpose: The Outcome Measures in Rheumatology (OMERACT) Systemic Lupus Erythematosus (SLE) Working Group was re-established in 2018 to update the SLE Core Outcome Set (COS)…Abstract Number: 0437 • ACR Convergence 2024
Describing Maternal Outcomes Among Veterans with a History of Systemic Lupus Erythematosus and Rheumatoid Arthritis
Background/Purpose: Veterans who utilize Department of Veterans Affairs (VA) maternity benefits, nearly half (42%) of whom represent racial or ethnic minority groups, have a high…Abstract Number: 0559 • ACR Convergence 2024
Predicting Disease Flares in Axial Spondyloarthritis Using Machine Learning in the METEOR-SpA Registry
Background/Purpose: Patients with axial spondyloarthritis (axSpA) frequently experience unforeseen disease flares that impact their quality of life. Identification of patients with high risk of flares…Abstract Number: 0619 • ACR Convergence 2024
Prevalence and Factors Predicting Hemophagocytic Lymphohistiocytosis in Hospitalized Patients with Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) complicated with hemophagocytic lymphohistiocystosis (HLH) can be life-threatening with mortality as high as 9.9%-10.5%. Estimates of the prevalence of HLH…Abstract Number: 0638 • ACR Convergence 2024
Soluble TNF RII in Lupus Nephritis as a Biomarker of Disease Activity and Treatment Response
Background/Purpose: Lupus Nephritis (LN) affects almost 60-70% patients of Systemic Lupus Erythematosus (SLE). Conventional markers of renal involvement i.e. proteinuria and renal biopsy have limitations…Abstract Number: 0646 • ACR Convergence 2024
Chart Audit of over 1,000 SLE Patients Reveals Biologic Treatment Choice Driven by Disease Manifestations
Background/Purpose: To better understand how US rheumatologists utilize biologics in the management of SLE, especially among those with cutaneous manifestations. No medication is currently FDA-approved…Abstract Number: 0548 • ACR Convergence 2024
Associations and Impact of Kinesiophobia on Patient Reported Outcomes and Performance-based Mobility Measures in Patients with Axial Spondyloarthritis
Background/Purpose: Kinesiophobia, defined as the fear of movement, poses a significant barrier to effective rehabilitation, functional recovery, and adequate physical activity. To investigate the impact…
- « Previous Page
- 1
- …
- 352
- 353
- 354
- 355
- 356
- …
- 2607
- Next Page »
